Clinical trials: Stage IV Breast Cancer
Metastatic HER2+ Advanced Breast Cancer
Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.
A retrospective study of de-identified (to preserve patient privacy) patient information from the Flatiron Health Database to describe 3L and 4L real-world (rw) outcomes (e.g.
- Trial name
- NCT06961331
- Testing
- Tucatinib, Trastuzumab, Capecitabine
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- Pfizer
HER2-positive Breast Cancer
A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
This study is designed to compare efficacy and safety of GQ1005 versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer patients previously treated with trastuzumab and taxane.
- Trial name
- NCT07673029
- Testing
- GQ1005, T-DM1
- Where
- 70 sites in China
- Volunteers
- 228 people
- Sponsor
- GeneQuantum Healthcare (Suzhou) Co., Ltd.
Metastatic Breast Cancer
Gemcitabine Plus Cisplatin Single Dose Versus Split Dose in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer After Failure of Anthracyclines and/or Taxanes
This is an open label, two arms, randomized, unblinded phase 2 study in patients with locally advanced or metastatic breast cancer who have been previously treated with anthracycline with/without taxane based regimen in the…
- Trial name
- NCT00192101
- Testing
- gemcitabine, cisplatin
- Where
- Saudi Arabia
- Volunteers
- 100 people
- Sponsor
- Eli Lilly and Company
HER2-positive Breast Cancer
A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M07D1 combined with Pertuzumab versus docetaxel plus Trastuzumab and Pertuzumab in patients with…
- Trial name
- NCT07518173
- Testing
- BL-M07D1, Pertuzumab, Trastuzumab
- Where
- 2 sites in China
- Volunteers
- 596 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Breast Carcinoma
Phase II Study of AS1402 Combined With Letrozole to Treat Breast Cancer
The aim of this study is to compare the overall tumour response rate per RECIST in postmenopausal women with metastatic or locally advanced breast cancer receiving AS1402 in combination with letrozole compared to letrozole alone
- Trial name
- NCT00770354
- Testing
- AS1402, Letrozole
- Where
- 2 sites in Russia
- Volunteers
- 110 people
- Sponsor
- Antisoma Research
HR+ Advanced or Metastatic Breast Cancer
Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer
The purpose of this Cohort Treatment Plan is to allow access to alpelisib for eligible patients diagnosed with hormone receptor positive, advanced or metastatic breast cancer harboring a phosphatidylinositol 3-kinase (PI3K)CA…
- Trial name
- NCT03706573
- Testing
- alpelisib
- Sponsor
- Novartis Pharmaceuticals
Advanced Breast Cancer
A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer
This study is an open-label, multicenter, Phase Ib/II clinical trial designed to evaluate the safety, tolerability, efficacy, and pharmacokinetic characteristics of QLC1401 tablets in combination with CDK4/6 inhibitors or mTOR…
- Trial name
- NCT07173556
- Testing
- QLC1401
- Volunteers
- 96 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Metastatic Breast Cancer, Triple Negative Breast Cancer
Triple Negative Breast Cancer Biomarker Study
Patients with metastatic or locally recurrent triple negative breast cancer (TNBC) who are scheduled for medically indicated surgical biopsy or resection of disease will be identified.
- Trial name
- NCT01111175
- Where
- 18 sites in United States
- Volunteers
- 14 people
- Sponsor
- US Oncology Research
Breast Cancer
A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)
Some human epidermal growth factor receptor 2 (HER-2) breast cancer patients do not respond or become resistant to current treatment. DS-8201a is a new experimental product that is a combination of an antibody and a drug.
- Trial name
- NCT03248492
- Testing
- DS-8201a
- Where
- 99 sites in United States, Belgium and 7 more
- Volunteers
- 253 people
- Sponsor
- Daiichi Sankyo
Triple-negative Breast Cancer
Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer
This study will look to establish the recommended biologic dose of AE37 in combination with pembrolizumab that will enhance the tumor-specific immune response and demonstrate efficacy in patients with advanced triple-negative…
- Trial name
- NSABP FB-14 (NCT04024800)
- Testing
- AE37 Peptide vaccine, Pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 29 people
- Sponsor
- NuGenerex Immuno-Oncology
Cancer
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00101972
- Testing
- monoclonal antibody RAV12
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- MacroGenics
Breast Neoplasms
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
The main purpose of this study is to compare progression-free survival for women with hormone receptor positive (HR+), human epidermal growth factor receptor (HER2) negative advanced breast cancer receiving either abemaciclib +…
- Trial name
- MONARCH 2 (NCT02107703)
- Testing
- Abemaciclib, Fulvestrant
- Where
- 146 sites in United States, Australia and 18 more
- Volunteers
- 669 people
- Sponsor
- Eli Lilly and Company
HER2-Negative Breast Cancer, Triple Negative Breast Cancer
Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
This study is designed as an open-label randomized parallel two-arm multicenter efficacy, pharmacokinetics and safety study of intravenously administered eribulin versus intravenously administered vinorelbine in Chinese…
- Conditions
- HER2-Negative Breast Cancer, Triple Negative Breast Cancer, Breast Cancer, Cancer of Breast
- Trial name
- NCT02225470
- Testing
- E7389 (Eribulin Mesylate), Vinorelbine injection
- Where
- 35 sites in China
- Volunteers
- 530 people
- Sponsor
- Eisai Co., Ltd.
Advanced or Metastatic Breast Cancer
A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world Database
The purpose of this real-world study is to look at breast cancer patients receiving Palbociclib using a large real-world database collected under real-world practice.
- Trial name
- NCT06962969
- Testing
- Ibrance
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
Metastatic Breast Cancer
Lipo-dox and Cyclophosphamide /5-Fluorouracil in Patients With Metastatic Breast Cancer
To determine the overall objective response rate of pegylated liposomal doxorubicin （Lipo-Dox）combined with cyclophosphamide/5-FU as second-line treatment in patients with metastatic breast cancer.
- Trial name
- NCT01451580
- Testing
- Lipo-Dox
- Where
- Taiwan
- Volunteers
- 47 people
- Sponsor
- TTY Biopharm
Breast Cancer
Study of BCD-115 in Women With ER(+) HER2(-) Local Advanced and Metastatic Breast Cancer
A Multicenter Open-label Non-comparative 2-Stage Phase 1a/1b Study to Assess the Safety and Pharmacokinetics of Oral BCD-115 (JSC BIOCAD, Russia) in Combination with Endocrine Therapy in Women with ER(+) HER2(-) Local Advanced…
- Trial name
- NCT03065010
- Testing
- BCD-115
- Where
- Russia
- Volunteers
- 6 people
- Sponsor
- Biocad
Breast Cancer
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
This Phase III trial adopts a randomized, open label, positive drug control, and multicenter trial design. Subjects who meet the criteria are randomly divided into 1:1 groups and receive treatment with TQB2102 injection or…
- Trial name
- NCT07003074
- Testing
- TQB2102 for Injection, Docetaxel combined + Trastuzumab +Pertuzumab
- Where
- 25 sites in China
- Volunteers
- 642 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Metastatic Breast Cancer
Metastatic Breast Cancer Treatment Planning
The overarching objective of this study is to close clinical knowledge and performance gaps by providing oncology clinicians with the latest advances and emerging research in the evidence-based and personalized treatment of…
- Trial name
- NCT03127332
- Testing
- Carevive CPS
- Sponsor
- Carevive Systems, Inc.
Breast Neoplasms, Neoplasm Metastasis
Study in Women With Metastatic Breast Cancer Whose Cancer Has Gotten Worse After Anthracycline and Taxane Therapy
This international study will study how metastatic breast cancer responds to the investigational drug treatment, what are the side effects of the investigational drug when given to women with metastatic breast cancer and how…
- Trial name
- NCT00067314
- Testing
- Edotecarin
- Where
- 19 sites in United States, Australia and 2 more
- Volunteers
- 65 people
- Sponsor
- Pfizer
Breast Neoplasms
Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer
Patients with advanced breast cancer to receive sunitinib (Sutent) once daily until disease progression.
- Trial name
- NCT00471276
- Testing
- sunitinib
- Where
- 31 sites in United States
- Volunteers
- 83 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.